ESMO 2026: Professor Huang Jun Interprets the CRIT Precision-Targeted Neoadjuvant Study in Locally Advanced Rectal Cancer

At ESMO 2026, Professor Huang Jun presented the CRIT phase 2 study, in which 49 patients with high-risk pMMR/MSS locally advanced rectal cancer achieved an overall pathological complete response (pCR) rate of 51.1%. Treatment was selected by RAS/BRAF status, using cetuximab beta or bevacizumab; pCR rates were 57.1% in the wild-type subgroup and 46.2% in the mutant subgroup. Of 47 patients who underwent surgery, 24 achieved pCR, and the R0 resection rate was 100%.